Spruce Biosciences, Inc. SPRB

SPRB Company Overview

Spruce Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare endocrine disorders with significant unmet medical need. The company has concentrated much of its development activity on diseases involving abnormalities in adrenal steroidogenesis and hormone regulation, particularly classic congenital adrenal hyperplasia (CAH). Spruce has operated within the broader biotechnology and rare disease therapeutics industry, with its business model historically centered on advancing proprietary drug candidates through clinical development and regulatory pathways.

The company’s principal product candidate has been tildacerfont, a non-steroidal corticotropin-releasing factor type 1 (CRF1) receptor antagonist investigated for the treatment of adult classic CAH. Spruce positioned itself around the goal of reducing dependence on chronic supraphysiologic steroid therapy, which is commonly associated with long-term complications. Founded in 2014 and headquartered in the United States, the company evolved from an early-stage rare disease research organization into a publicly traded biotechnology company listed on Nasdaq under the ticker SPRB. Public disclosures and filings indicate that following clinical trial setbacks related to tildacerfont, the company evaluated strategic alternatives and operational restructuring measures.